| Literature DB >> 22894616 |
Abstract
Pathogens that produce extended spectrum β-lactamases (ESBLs), plasmid-mediated AmpC β-lactamases, and carbapenemases may appear falsely susceptible to β-lactam antibiotics in the laboratory. Infected patients may be treated with inappropriate antibiotics if laboratories do not perform accurate tests to detect these resistance mechanisms. Furthermore the resistant pathogens may spread undetected to amplify the therapeutic and infection control challenge. This review makes a case for why and how laboratories should perform tests to detect β-lactamase-mediated resistance in gram-negative pathogens.Entities:
Mesh:
Substances:
Year: 2013 PMID: 22894616
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116